An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease

N Engl J Med. 2021 Aug 26;385(9):856-857. doi: 10.1056/NEJMc2111960. Epub 2021 Jul 28.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized
  • Humans

Substances

  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized
  • aducanumab